$7.41
5.86%
Nasdaq, Sep 02, 10:00 pm CET
ISIN
US55234L1052
Symbol
LYRA

Lyra Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Lyra Therapeutics Inc Classifications & Recommendation:

Hold
67%
Sell
33%

Lyra Therapeutics Inc Price Target

Target Price $23.46
Price $7.41
Potential
Number of Estimates 4
4 Analysts have issued a price target Lyra Therapeutics Inc 2026 . The average Lyra Therapeutics Inc target price is $23.46. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 9 analysts: 0 Analysts recommend Lyra Therapeutics Inc to buy, 6 to hold and 3 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Lyra Therapeutics Inc stock has an average upside potential 2026 of . Most analysts recommend the Lyra Therapeutics Inc stock at Hold.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 1.53 0.78
1.92% 49.28%
EBITDA Margin -3,938.56% -2,281.96%
5.84% 42.06%
Net Margin -6,107.19% -1,943.89%
52.00% 68.17%

6 Analysts have issued a sales forecast Lyra Therapeutics Inc 2025 . The average Lyra Therapeutics Inc sales estimate is

$776k
Unlock
. This is
0.78% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$1.6m 104.55%
Unlock
, the lowest is
$392k 49.09%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $1.5m 1.92%
2025
$776k 49.28%
Unlock
2026
$1.7m 123.45%
Unlock
2027
$11.7m 574.39%
Unlock
2028
$37.4m 219.52%
Unlock
2029
$65.6m 75.53%
Unlock
2030
$94.6m 44.31%
Unlock
2031
$112m 18.50%
Unlock
2032
$128m 14.40%
Unlock

3 Analysts have issued an Lyra Therapeutics Inc EBITDA forecast 2025. The average Lyra Therapeutics Inc EBITDA estimate is

$-17.7m
Unlock
. This is
49.89% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-18.2m 48.42%
Unlock
, the lowest is
$-17.0m 51.86%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-60.3m 7.65%
2025
$-17.7m 70.62%
Unlock

EBITDA Margin

2024 -3,938.56% 5.84%
2025
-2,281.96% 42.06%
Unlock

6 Lyra Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Lyra Therapeutics Inc net profit estimate is

$-15.1m
Unlock
. This is
61.17% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-2.5m 93.51%
Unlock
, the lowest is
$-33.6m 13.62%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-93.4m 49.07%
2025
$-15.1m 83.86%
Unlock
2026
$-16.0m 5.77%
Unlock
2027
$-11.2m 30.03%
Unlock
2028
$-6.7m 40.23%
Unlock
2029
$-2.2m 66.87%
Unlock

Net Margin

2024 -6,107.19% 52.00%
2025
-1,943.89% 68.17%
Unlock
2026
-919.83% 52.68%
Unlock
2027
-95.40% 89.63%
Unlock
2028
-17.84% 81.30%
Unlock
2029
-3.37% 81.11%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -71.75 -9.25
14.02% 87.11%
P/E negative
EV/Sales negative

6 Analysts have issued a Lyra Therapeutics Inc forecast for earnings per share. The average Lyra Therapeutics Inc EPS is

$-9.25
Unlock
. This is
67.87% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-1.54 94.65%
Unlock
, the lowest is
$-20.58 28.52%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-71.75 14.02%
2025
$-9.25 87.11%
Unlock
2026
$-9.79 5.84%
Unlock
2027
$-6.84 30.13%
Unlock
2028
$-4.09 40.20%
Unlock
2029
$-1.36 66.75%
Unlock

P/E ratio

Current -0.26 23.22%
2025
-0.80 210.80%
Unlock
2026
-0.76 5.00%
Unlock
2027
-1.08 42.11%
Unlock
2028
-1.81 67.59%
Unlock
2029
-5.46 201.66%
Unlock

Based on analysts' sales estimates for 2025, the Lyra Therapeutics Inc stock is valued at an EV/Sales of

-22.67
Unlock
and an P/S ratio of
15.71
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current -22.85 10.46%
2025
-22.67 0.79%
Unlock
2026
-10.14 55.25%
Unlock
2027
-1.50 85.17%
Unlock
2028
-0.47 68.70%
Unlock
2029
-0.27 43.03%
Unlock
2030
-0.19 30.72%
Unlock
2031
-0.16 15.61%
Unlock
2032
-0.14 12.56%
Unlock

P/S ratio

Current 15.83 36.78%
2025
15.71 0.73%
Unlock
2026
7.03 55.25%
Unlock
2027
1.04 85.17%
Unlock
2028
0.33 68.71%
Unlock
2029
0.19 43.01%
Unlock
2030
0.13 30.72%
Unlock
2031
0.11 15.61%
Unlock
2032
0.10 12.60%
Unlock

Current Lyra Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Aug 14 2025
HC Wainwright & Co.
Locked
Locked
Locked Jun 10 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 14 2025
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Aug 14 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jun 10 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 14 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today